Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the three approved proteasome inhibitors, carfilzomib, bortezomib, and ixazomib.

Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with immunomodulatory agents.

Dr. Philip McCarthy discusses which patients are transplant-eligible and what factors may limit their options.

Dr. Nooka discusses the crucial steps in identifying if your myeloma patient with cardiac history should receive carfilzomib and if so, when.

Join Dr. Usmani as he recommends the steps community oncologists should take to differentiate between, and provide ideal follow-up to, MGUS and smoldering MM patients.

Join Dr. Orlowski as he explains when to use daratumumab-lenalidomide-dexamethasone versus daratumumab-bortezomib-dexamethasone in clinical practice with multiple myeloma patients.

Join Dr. Usmani as he details the lab, biopsy-specific, and imaging-specific tests the community oncologist needs to consider when establishing a multiple myeloma diagnosis.

Join Dr. Orlowski as he defines aggressive symptomatic relapse and explains which drug regimens are recommended for rapidly progressing disease.

Join Dr. Orlowski as he recommends drug regimens for treating patients with asymptomatic biochemical relapse with slow versus rapid rise in M-protein levels.

Join Dr. Stadtmauer as he explains how to define and measure minimal residual disease (MRD) in patients with multiple myeloma, as well as the clinical implications of this technique to patient care.